VVelarionINTELLIGENCE
Sign inStart free trial
Start free trial
Biopharma & Life Sciences

QuidelOrtho Executive Compensation (FY25)

QDEL · Executive and director compensation, fiscal 2022 to 2025
Chief executive, fiscal 2025
◇
Brian Blaser
Latest say-on-pay support
=
June 16, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Intel, $5,000/year: one seat · one year · every company we cover, with dashboards, peer screens and board-ready briefs.
See every company’s exec pay — free for 3 days, no cardSee the plan and pricing

The QuidelOrtho brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
Data as of November 5, 2026Latest filing (8-K): June 16, 2026
9 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
QuidelOrtho brief$500Get the executive brief
Velarion Intel, one year, every company
331 figures on this page: 327 cited to the filing that reported them, 4 calculated from figures it prints. See the citations
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Brian Blaser: $15,044,937 → $11,255,782 (25.2% lower)
CEO pay ratio: 168:1 → 154:1 (8.3% lower)

Frequently asked questions

Answers drawn from the data on this page.
Who is QuidelOrtho's chief executive and what were they paid?
Total compensation for Brian Blaser, President and Chief Executive Officer, came to $11,255,782 in fiscal 2025. Blaser's total was 25.2% lower than the $15,044,937 reported for fiscal 2024.
What was QuidelOrtho's say-on-pay result?
Shareholders recorded 97.4% support for the say-on-pay proposal at the meeting held June 16, 2026 for fiscal 2025.
Which companies are in QuidelOrtho's peer group?
The disclosed peer group includes Bio-Rad Laboratories, Inc., Bruker Corporation, CONMED Corporation, Dentsply Sirona Inc. and Enovis Corporation, among others.
What is QuidelOrtho's chief executive pay ratio?
The company reported a chief executive pay ratio of 154:1 for fiscal 2025, against median employee compensation of $73,316.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas Bryant
Former President and CEO
◇◇◇◇◇—◇◇
Robert Bujarski
Former Interim President, EVP and COO
Served on an interim basis
◇◇◇◇◇—◇◇
Michelle Hodges
CLO
◇◇◇◇◇—◇◇
Joseph Busky
Chief Financial Officer
◇◇◇◇◇—◇◇
Werner Kroll
SVP, Research and Development
◇◇◇—◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Douglas Bryant
Former President and CEO
◇◇◇◇——◇◇
Robert Bujarski
Former Interim President, EVP and COO
Served on an interim basis
◇◇◇◇——◇◇
Michael Iskra
Former Interim CEO, EVP and CCO
Served on an interim basis
◇◇◇◇——◇◇
Joseph Busky
Chief Financial Officer
◇◇◇◇——◇◇
Werner Kroll
SVP, Research and Development
◇◇◇—◇—◇◇
Michelle Hodges
CLO
◇◇◇◇——◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Blaser
President and CEO
◇—◇—◇—◇◇
Douglas Bryant
Former President and CEO
Departed during or after this year
◇—◇—◇—◇◇
Robert Bujarski
Former Interim President, EVP and COO
Departed during or after this year
◇—◇———◇◇
Michael Iskra
Former Interim CEO, EVP and CCO
Departed during or after this year
◇—◇———◇◇
Joseph Busky
CFO
◇—◇—◇—◇◇
Michelle Hodges
CLO
◇—◇◇◇—◇◇
Jonathan Siegrist
EVP of R&D and CTO
◇◇◇—◇—◇◇
Patrick Klein
Former SVP, CAO
Departed during or after this year
◇—◇◇——◇◇
Philip McLellan
COO
◇—◇◇◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Brian Blaser
President and Chief Executive Officer
◇—◇—◇—◇◇
Joseph Busky
Chief Financial Officer
◇◇◇—◇—◇◇
Michelle Hodges
Former Chief Legal Officer
Departed during or after this year
◇◇◇◇◇—◇◇
Philip McLellan
Chief Operations Officer
◇◇◇◇◇—◇◇
Jonathan Siegrist
Executive Vice President of R&D and Chief Technology Officer
◇◇◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Brian J. BlaserPSU◇◇◇—◇—◇
Brian J. BlaserRSU◇——◇——◇
Jonathan P. SiegristOPTION◇——◇—◇◇
Jonathan P. SiegristRSU◇——◇——◇
Joseph M. BuskyPSU◇◇◇—◇—◇
Joseph M. BuskyRSU◇——◇——◇
Michelle A. HodgesRSU◇——◇——◇
Michelle A. HodgesOPTION◇——◇—◇◇
Michelle A. HodgesRSU◇——◇——◇
Philip D. McLellanOPTION◇——◇—◇◇
Philip D. McLellanRSU◇——◇——◇
Fiscal 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Brian BlaserRSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Jonathan SiegristRSU◇◇——
Option◇—◇01/29/35
RSU◇◇——
Joseph BuskyRSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/28/33
RSU◇◇——
Michelle HodgesRSU◇◇——
Option◇—◇01/29/35
RSU◇◇——
Option◇—◇02/08/34
RSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇03/28/33
RSU◇◇——
Option◇—◇01/31/32
RSU◇◇——
Philip McLellanRSU◇◇——
Option◇—◇01/29/35
Option◇—◇04/22/34
RSU◇◇——
Option◇—◇04/26/33
RSU◇◇——
Option◇—◇01/31/32
RSU◇◇——
RSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Jonathan Siegrist
Executive Vice President of R&D and Chief Technology Officer · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Joseph Busky
Chief Financial Officer · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇
Michelle Hodges
Former Chief Legal Officer · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Benefits continuation on change in control◇
Benefits continuation◇
Philip McLellan
Chief Operations Officer · Change-in-control agreement
Severance multiple◇
Change-in-control multiple◇
Equity acceleration on change in control◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Kenneth F. Buechler, Ph.D
Board chair
◇◇————◇
Kenneth J. Widder, M.D
◇◇————◇
Edward L. Michael
◇◇————◇
Ann D. Rhoads
◇◇————◇
John R. Chiminski
◇◇————◇
Mary Lake Polan, M.D., Ph.D., M.P.H
◇◇————◇
R. Scott Huennekens
◇◇————◇
Joseph D. Wilkins Jr
◇◇————◇
Evelyn S. Dilsaver
◇◇————◇
Matthew W. Strobeck, Ph.D
◇◇————◇
Brian J. Blaser served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Compensation committee chair◇
Nominating and governance chair◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Bio-Rad Laboratories, Inc. BIO
  • Bruker Corporation BRKR
  • CONMED Corporation CNMD
  • Dentsply Sirona Inc. XRAY
  • Enovis Corporation ENOV
  • Envista Holdings Corporation NVST
  • Evolent Health, Inc. EVH
  • Exact Sciences Corporation EXAS
  • Fortrea Holdings Inc. FTRE
  • ICU Medical, Inc. ICUI
  • Integer Holdings Corporation ITGR
  • Integra LifeSciences Holdings Corporation IART
  • Masimo Corporation MASI
  • Omnicell, Inc. OMCL
  • RadNet, Inc. RDNT
  • Sotera Health Company SHC
  • Teladoc Health, Inc. TDOC
  • Teleflex Inc. TFX
  • Veradigm Inc. MDRX

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 16, 2026=◇◇◇
2024May 20, 2025=◇◇◇
2023May 14, 2024=◇◇◇
2022May 16, 2023=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- Brian Blaser (President and Chief Executive Officer), FY2025 total compensation $11,255,782 (base salary $1,000,000) [exec_comp, SEC accession 0001906324-26-000018, filed 2026-04-27]

See a complete sample report

Answered within 24 hours, every figure cited to its SEC filing. This is a one-off report: no refunds.

Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when QuidelOrtho files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact QuidelOrtho disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where QuidelOrtho sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $500
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether QuidelOrtho's disclosed peer group is defensible, who names QuidelOrtho back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
331 figures on this page: 327 cited to the filing that reported them, 4 calculated from figures it prints.
327 cited to the filing
4 calculated from the filing

Documents cited

  1. 0001193125-26-272707
    Proposal No. 2 The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the votes set forth in the table below: Votes For Votes Against
  2. 0001906324-26-000018
    CEO Pay Ratio · Director Compensation · Director Compensation Table · Grants of Plan-Based Awards in Fiscal Year 2025 · and 2 more sections
  3. 0001193125-25-127604
    Proposal No. 3 The Company’s stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers by the votes set forth in the table below: Votes For Votes Against
  4. 0001906324-25-000045
    Summary Compensation Table
  5. 0001906324-25-000035
  6. 0001906324-24-000034
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001906324-24-000018
    Summary Compensation Table
  8. 0001906324-23-000036
  9. 0001906324-23-000020
    Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “QuidelOrtho executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/QDEL (accessed 2026).
Short form: data: Velarion

The QuidelOrtho brief, $500

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $500 for the board report; $900 for both.
Get the executive briefGet the board briefNo account needed.
9 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about QuidelOrtho and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers QuidelOrtho discloses

The companies named in QDEL's own disclosed peer group.

Bio-Rad Laboratories, Inc.Bruker CorporationCONMED CorporationDentsply Sirona Inc.Enovis CorporationEnvista Holdings CorporationEvolent Health, Inc.Exact Sciences CorporationFortrea Holdings Inc.ICU Medical, Inc.Integer Holdings CorporationIntegra LifeSciences Holdings CorporationMasimo CorporationOmnicell, Inc.RadNet, Inc.Sotera Health CompanyTeladoc Health, Inc.Teleflex Inc.Veradigm Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy